Myoma Uteri

myomauteri-1-0-25kapak

Aproach to Myoma in the Postmenopausal Period

Serpil Aydoğmuş

İzmir Katip Çelebi University, Faculty of Medicine, Department of Gynecology and Obstetric, İzmir, Türkiye

Aydoğmuş S. Aproach to Myoma in the Postmenopausal Period. Yavuz AF, ed. Myoma Uteri. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.165-174.

ABSTRACT

Uterine leiomyoma is one of the most common gynecologic pathologies which frequently affect the perimenopausal women. Leiomyomas are hormone-dependent tumors. Estrogen and progesterone have a critical role on development of leiomyomas. Despite the common knowledge that uterine leiomyomas stabilize or regress after menopause, a considerable number of postmenopausal patients are reported to require surgery for uterine leiomyomas. Postmenopausal patients had a higher incidence of UL variants than premenopausal patients. lipoleiomyoma and cellular leiomyomas are more likely to occur in postmenopausal women. Most relevant symptoms are abnormal uterine bleeding and pelvic pain or pressure. Differential diagnosis between leiomyoma and sarcoma is important in the management of uterine leiomyomas especially in postmenopausal women. There are multiple treatment options like tibolone, aromatase inhibitors, selective estrogen receptor modulators, uterine artery embolization and selective progesterone receptor modulators, but surgery remains the favourite method. Hormone replacement treatment to postmenopausal women with myomas may cause to fibroid regrowth, patients will usually remain asymptomatic despite the increase in the size of the leiomyoma. Further investigations are needed for describing possible diagnostic tools that may help to differential diagnosis of leiomyomas from sarcomas and also for new treatment options.

Keywords: Leiomyoma; Postmenopausal; Uterine neoplasms; Uterine fibroid

Referanslar

  1. Bulun SE. Uterine fibroids. N Engl J Med 2013;369(14):1344-55. [Crossref]  [PubMed]
  2. Ghosh S, Naftalin J, Imrie R, Hoo WL. Natural history of uterine fibroids: a radiological perspective. Current Obstet Gynecol Rep. 2018;7 (3):117-121. [Crossref]  [PubMed]  [PMC]
  3. Stewart E, Cookson C, Gandolfo R, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG Int J Obstet Gynaecol 2017;124:1501-12. [Crossref]  [PubMed]
  4. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004; 10: 207-220. [Crossref]  [PubMed]
  5. Templeman C, Marshall SF, Clarke CA et al. Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril 2009; 92: 1436-144. [Crossref]  [PubMed]  [PMC]
  6. Dolmans MM, Petraglia F, Catherino WH, Donnez J. Pathogenesis of uterine fibroids: current understanding and future directions. Fertil Steril 2024;122:6-1. [Crossref]  [PubMed]
  7. Cetin E, Al-Hendy A, Ciebiera M: Non-hormonal mediators of uterine fibroid growth. Curr Opin Obstet Gynecol. 2020, 32:361-70. [Crossref]  [PubMed]  [PMC]
  8. Segars JH, Parrott EC, Nagel JD et al. Proceedings from the third National Institutes of Health international congress on advances in uterine leiomyoma research: Comprehensive review, conference summary and future recommendations. Hum Reprod Update 2014; 20: 309-333. [Crossref]  [PubMed]  [PMC]
  9. Oi Y, Katayama K, Hirata G, Ishidera Y, Yoshida H, Shigeta H. Significance of postmenopausal uterine leiomyomas: Focus on variants. J Obstet Gynaecol Res. 2018 Aug;44(8):1445-1450. [Crossref]  [PubMed]
  10. Moravek MB, Bulun SE. Endocrinology of Uterine Fibroids: Steroid Hormones, Stem Cells, and Genetic Contribution. Curr. Opin. Obstet. Gynecol. 2015, 27, 276-283. [Crossref]  [PubMed]  [PMC]
  11. Reis FM, Bloise E, Ortiga-Carvalho TM. Hormones and pathogenesis of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:13-24. [Crossref]  [PubMed]
  12. Borahay MA, Asoglu MR, Mas A, et al. Estrogen receptors and signaling in fibroids: role in pathobiology and therapeutic implications. Reprod Sci 2017;24 (9):1235-44. [Crossref]  [PubMed]  [PMC]
  13. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003; 111: 1037-1054. [Crossref]  [PubMed]  [PMC]
  14. Ciarmela P, Islam MS, Reis FM, et al. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update. 2011; 17:772-790. [Crossref]  [PubMed]  [PMC]
  15. Asano R, Asai-Sato M, Miyagi Y, et al. Aberrant expression of erythropoietin in uterine leiomyoma: implications in tumor growth. Am J Obstet Gynecol. 2015; 213: 199.e1-199.e8. [Crossref]  [PubMed]
  16. Jayes FL, Liu B, Feng L, Aviles-Espinoza N, Leikin S, Leppert PC. Evidence of biomechanical and collagen heterogeneity in uterine fibroids. PLoS One. 2019;14(4):e0215646. [Crossref]  [PubMed]  [PMC]
  17. Shigeta H, Asano R, Oi Y, et al. Uterine Leiomyoma in Postmenopausal Women: Possible Reasons for Growth and Differential Diagnosis. Gynecol Reprod Health. 2021; 5(6): 1-8. [Crossref]
  18. Tanioka S, Asano R, Wakabayashi R, Hayashi H, Shigeta H. Possible significance of degeneration and decreased expression of progesterone receptor in postmenopausal uterine leiomyoma. BMC Womens Health. 2022, 16;22(1):346. [Crossref]  [PubMed]  [PMC]
  19. Nisolle M, Gillerot S, Casanas -Roux F, Squifet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin releasing hormone agonist therapy. Hum Reprod. 1999;14(11):2844-50. [Crossref]  [PubMed]
  20. Moro E, Degli Esposti E, Borghese G, Manzara F, Zanello M, Raimondo D, et al. The Impact of Hormonal Replacement Treatment in Postmenopausal Women with Uterine Fibroids: A State-of-the-Art Review of the Literature. Medicina (Kaunas). 2019;55(9):549. [Crossref]  [PubMed]  [PMC]
  21. Foth D, Röhl F-W, Friedrich C, Tylkoski H, Rabe T, Römer T, et al. Symptoms of uterine myomas: data of an epidemiological study in Germany. Arch Gynecol Obstet. 2017;295:415-26. [Crossref]  [PubMed]
  22. Uimari O, Subramaniam KS, Vollenhoven B, Tapmeier TT. Uterine Fibroids (Leiomyomata) and Heavy Menstrual Bleeding. Front Reprod Health. 2022;4;4:818243. [Crossref]  [PubMed]  [PMC]
  23. Mension E, Carmona F, Vannuccini S, Chapron C. Clinical signs and diagnosis of fibroids from adolescence to menopause. Fertil Steril. 2024;122(1):12-19. [Crossref]  [PubMed]
  24. Hodge JC, Pearce KE, Clayton AC, et al. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol. 2014; 210: 572.e1-572. e7. [Crossref]  [PubMed]  [PMC]
  25. Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci USA. 2008; 105: 19887-19892. [Crossref]  [PubMed]  [PMC]
  26. Naz S, Rehman A, Riyaz A, Jehangir F, Naeem S, Iqbal T. Leiomyoma: its variants and secondary changes a five -year study. J Ayub Med Coll Abbottabad. 2019;31(2):192-5.
  27. Yorita K, Tanaka Y, Hirano K, Kai Y, Arii K, Nakatani K, et al. A subserosal, pedunculated, multilocular uterine leiomyoma with ovarian tumor -like morphology and histological architecture of adenomatoid tumors: a case report and review of the literature. J Med Case Rep. 2016;10(1):352. [Crossref]  [PubMed]  [PMC]
  28. Deligdisch L, Hirschmann S, Altchek A. Pathologic changes in gonadotro pin releasing hormone agonist analogue treated uterine leiomyomata. Fertil Steril. 1997;67(5):837-41. [Crossref]  [PubMed]
  29. Ishidera Y, Yoshida H, Oi Y, et al. Analysis of uterine corporeal mesenchymal tumors occurring after menopause. BMC Womens Health. 2019; 19: 13. [Crossref]  [PubMed]  [PMC]
  30. Okamoto T, Koshiyama M, Yamamoto K. Rapidly growing leiomyoma in a postmenopausal woman. J Obstet Gynaecol Res. 2004;30(4):316-8. [Crossref]  [PubMed]
  31. Sommer EM, Balkwill A, Reeves G, Green J, Beral DV, Coffey K, et al. Effects of obesity and hormone therapy on surgically-confirmed fibroids in postmenopausal women. Eur J Epidemiol. 2015;30(6):493-9. [Crossref]  [PubMed]  [PMC]
  32. Dandolu V, Singh R, Lidicker J, Harmanli O. BMI and uterine size: is there any relationship? Int J Gynecol Pathol. 2010;29:568-71. [Crossref]  [PubMed]
  33. Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. AfricanAmerican heritage, reproductive history, body size, and smoking. Am J Epidemiol. 2001;153:1-10. [Crossref]  [PubMed]
  34. Wise LA, Palmer JR, Spiegelman D, Harlow BL, Stewart EA, Adams-Campbell LL, et al. Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. Epidemiology. 2005;16:346-54. [Crossref]  [PubMed]  [PMC]
  35. Parazzini F, Chiaffarino F, Polverino G, Chiantera V, Surace M, La Vecchia C. Uterine fibroids risk and history of selected medical conditions linked with female hormones. Eur J Epidemiol. 2004;19:249-53. [Crossref]  [PubMed]
  36. Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. Reprod Biomed Online. 2006; 12(5):542-551. PubMed: 16790096. [Crossref]  [PubMed]
  37. Wise LA, Laughlin-Tommaso SK. Epidemiology of Uterine Fibroids: From Menarche to Menopause. Clin Obstet Gynecol. 2016;59(1):2-24. [Crossref]  [PubMed]  [PMC]
  38. Randell KM, Honkanen RJ, Tuppurainen MT, et al. Fracture risk and bone density of peri- and early postmenopausal women with uterine leiomyomas. Maturitas 2006;53(3):333-42. [Crossref]  [PubMed]
  39. Mao J, Pfeifer S, Zheng XE, et al. Population-based estimates of the prevalence of uterine sarcoma among patients with leiomyomata undergoing surgical treatment. JAMA Surg. 2015; 150: 368-370. [Crossref]  [PubMed]
  40. Wang Y, Zhao Y, Shi C, Li J, Huang X. Development and Validation of a Nomogram to Predict the Risk of Special Uterine Leiomyoma Pathological Types or Leiomyosarcoma in Postmenopausal Women: A Retrospective Study. Risk Manag Healthc Policy. 2024;21;17:1669-1685. [Crossref]  [PubMed]  [PMC]
  41. Duk, J.M.; Bouma, J.; Burger, G.T.N.; Nap, M.; De Bruijn, H.W.A. CA 125 in serum and tumor from patients with uterine sarcoma. Int. J. Gynecol. Cancer 1994, 4, 156-160. [Crossref]  [PubMed]
  42. Juang, C.M.; Yen, M.S.; Horng, H.C.; Twu, N.F.; Yu, H.C.; Hsu, W.L. Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma. Eur. J. Gynaecol. Oncol. 2006, 27, 370-374. [Link]
  43. Yilmaz N, Sahin I, Kilic S, Ozgu E, Gungor T, Bilge U. Assessment of the predictivity of preoperative serum CA 125 in the differential diagnosis of uterine leiomyoma and uterine sarcoma in the Turkish female population. Eur. J. Gynaecol. Oncol. 2009,30, 412414. [Link]
  44. Skorstad M, Kent A, Lieng M. Preoperative evaluation in women with uterine leiomyosarcoma. A nationwide cohort study. Acta Obstet. Gynecol. Scand. 2016, 95, 1228-1234. [Crossref]  [PubMed]
  45. Zhang F, Liu Y, Quan Q, Meng Y, Mu X. Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System. Cancer Manag. Res. 2021,13, 4657-4664. [Crossref]  [PubMed]  [PMC]
  46. Żak K, Zaremba B, Rajtak A, Kotarski J, Amant F, Bobiński M. Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions. Cancers (Basel). 2022;14(8):1966. [Crossref]  [PubMed]  [PMC]
  47. Zhang G, Yu X, Zhu L, Fan Q, Shi H, Lang J. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid. BMC Cancer 2020, 20,514. [Crossref]  [PubMed]  [PMC]
  48. Wen KC, Horng HC, Wang PH, Chen YJ, Yen MS, Ng HT, et al. Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. Taiwan J Obstet Gynecol. 2016;55(4):463-71. [Crossref]  [PubMed]
  49. Liu G, Ke L-C, Sun S-R. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: A meta-analysis. Medicine 2018, 97, e12176. [Crossref]  [PubMed]  [PMC]
  50. Raffone A, Raimondo D, Neola D, Travaglino A, Raspollini A, Giorgi M, et al. Diagnostic accuracy of ultrasound in the diagnosis of uterine leiomyomas and sarcomas. J Minim Invasive Gynecol 2024;31:28-36.e1. [Crossref]  [PubMed]
  51. Torkzaban M, Machado P, Gupta I, Hai Y, Forsberg F. Contrast-enhanced ultrasound for monitoring non-surgical treatments of uterine fibroids: a systematic review. Ultrasound Med Biol 2021;47:3-18. [Crossref]  [PubMed]  [PMC]
  52. Brohl AS, Li L, Andikyan V, et al. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist. 2015; 20: 433-439. [Crossref]  [PubMed]  [PMC]
  53. Ip PP, Tse KY, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol. 2010; 17: 91-112. [Crossref]  [PubMed]
  54. Ali M, Chaudhry ZT, Al-Hendy A. Uterine Fibroids in Postmenopausal Women. In: Metwally M, Li T-C, eds. Modern Management of Uterine Fibroids. Cambridge University Press; 2020:184-189. [Crossref]
  55. Palomba S, Sena T, Morelli M, et al. Effect of different doses of progestin on uterine leiomyomas in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2002;102(2):199-201. [Crossref]  [PubMed]
  56. Ang WC, Farrell E, Vollenhoven B. Effect of hormone replacement therapies and selective oestrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric 2001;4 (4):284-92. [Crossref]  [PubMed]
  57. Schwartz LB, Rutkowski N, Horan C, et al. Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation. J Ultrasound Med. 1998; 17: 699-703. [Crossref]  [PubMed]
  58. Palomba S, Sammartino A, Di Carlo C, Affinito P, Zullo F, Nappi C. Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil. Steril. 2001, 76, 38-43. [Crossref]  [PubMed]
  59. Palomba S, Orio F, Russo T, Falbo A, Tolino A, Lombardi G, et al. Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. Fertil Steril. 2005, 84, 154-161. [Crossref]  [PubMed]
  60. Chang IJ, Hong GY, Oh YL, et al. Effects of menopausal hormone therapy on uterine myoma in menopausal women. J Menopausal Med 2013;19(3):123-9. [Crossref]  [PubMed]  [PMC]
  61. Cramer SF, Marchetti C, Freedman J, Padela A. Relationship of myoma cell size and menopausal status in small uterine leiomyomas. Arch Pathol Lab Med 2000;124(10):1448-53. [Crossref]  [PubMed]
  62. Kaunitz AM. Aromatase inhibitor therapy for uterine bleeding in a postmenopausal woman with leiomyomata. Menopause 2007;14 (5):941-3. [Crossref]  [PubMed]
  63. Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril.2010;93(1):192-8. [Crossref]  [PubMed]
  64. Ulin M, Ali M, Chaudhry ZT, Al-Hendy A, Yang Q. Uterine fibroids in menopause and perimenopause. Menopause. 2020;27(2):238-242. [Crossref]  [PubMed]  [PMC]
  65. Ekanem E, Talaulikar V. Medical Therapy for Fibroids: What Next for Ulipristal Acetate? Adv Ther. 2021;38(1):137-148. [Crossref]  [PubMed]  [PMC]
  66. Chrisman HB, Minocha J, Ryu RK, Vogelzang RL, Nikolaidis P, Omary RA. Uterine artery embolization: a treatment option for symptomatic fibroids in postmenopausal women. J Vasc Interv Radiol. 2007;18(3):451-4. [Crossref]  [PubMed]
  67. Oindi FM, Mutiso SK, Obura T. Port site parasitic leiomyoma after laparoscopic myomectomy: a case report and review of the literature. J Med Case Rep. 2018;12(1):339. [Crossref]  [PubMed]  [PMC]
  68. Kyriakopoulos K, Domali E, Stavrou S, Rodolakis A, Loutradis D, Drakakis P. Recurrent benign leiomyomas after total abdominal hysterectomy. Rich or poor estrogenic environment may lead to their recurrence? International Journal of Surgery Case Reports. 2018;44:191-3. [Crossref]  [PubMed]  [PMC]
  69. Brodie A, Rai J, Alevizopoulos A. et al. Paraurethral leiomyoma in a post-menopausal woman: a case report. Afr J Urol 29, 13 (2023). [Crossref]
  70. Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, et al. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022 Jul 13;43(4):678-719. [Crossref]  [PubMed]  [PMC]